Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.
about
Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infectionPharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancerEvaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensAntimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patientsContinuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis.Improved outcomes of patients with end-stage cystic fibrosis requiring invasive mechanical ventilation for acute respiratory failure.Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia.Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation.Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia.Temporary interruption of ceftazidime continuous infusion without reduction of activity: a computer-assisted simulation.Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies.
P2860
Q24675002-6434F87E-9677-4BE9-8E86-8F9B8D062AF7Q26825326-17BDB256-19B6-4DFC-AE1B-42E274F0EFE6Q33770046-0BDC6CB5-7BED-400D-8D18-B1EB28047022Q33938048-FCA2804B-FAB7-414D-9936-FBB6EFE61445Q34381321-0A6E8061-5914-40F3-B478-F44CDEE15B42Q35136449-60E6C566-C03E-440B-997C-4610FDC41AE9Q35138316-EE243705-1E63-421F-B3F5-C142AB88C28BQ37333080-DDE9805A-D156-4402-92CF-3B8BAA810813Q37909115-8C1133C5-FF14-46AC-B9F1-4617E04A70F0Q38117578-CCA93C28-AAB9-43AA-AEB4-AA8337AC78D3Q38896040-DAF86FAB-D43B-45EE-B38B-D1F11E318F5EQ40186288-1B0163A9-2D8E-4698-9DFE-678132B6EFF3Q40206253-31BE8C37-5838-4834-B490-26DE14798288Q40586250-0485653D-1E8F-47A2-862C-4AC1F1BC19DCQ40948657-39CFDCB9-2D2F-4EC4-A2CB-2A6C15E4F793Q43410703-2A4DFAE3-D3C0-4BB6-9FD9-58F27C8563AAQ43758472-EA1B2AAC-FB8D-4F36-9796-EC70DEFDCCE2Q47574617-0030FA93-29BE-49AB-B39D-F19281DC8CC8
P2860
Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Continuous infusion of ceftazi ...... s with acute myeloid leukemia.
@en
type
label
Continuous infusion of ceftazi ...... s with acute myeloid leukemia.
@en
prefLabel
Continuous infusion of ceftazi ...... s with acute myeloid leukemia.
@en
P2093
P2860
P356
P1476
Continuous infusion of ceftazi ...... s with acute myeloid leukemia.
@en
P2093
H G De Vries-Hospers
P De Jonge
P2860
P2888
P304
P356
10.1007/BF02310354
P577
1995-03-01T00:00:00Z
P6179
1036855831